Your browser doesn't support javascript.
More light on cancer and COVID-19 reciprocal interaction.
Brest, Patrick; Mograbi, Baharia; Hofman, Paul; Milano, Gerard.
  • Brest P; Université Côte d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France.
  • Mograbi B; Université Côte d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France.
  • Hofman P; Université Côte d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France.
  • Milano G; Université Côte d'Azur, CHU-Nice, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Hospital-Integrated Biobank (BB-0033-00025), 06001, Nice, France.
Br J Cancer ; 124(8): 1344-1345, 2021 04.
Article in English | MEDLINE | ID: covidwho-1060915
ABSTRACT
Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer with attention paid to the modulation by cancer treatments of both ADAM17 and TMPRSS2, the proteases which control ACE2 processing, the SARS-CoV-2 target.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Serine Endopeptidases / ADAM17 Protein / COVID-19 / Neoplasms Type of study: Observational study Topics: Long Covid Limits: Humans Language: English Journal: Br J Cancer Year: 2021 Document Type: Article Affiliation country: S41416-020-01246-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Serine Endopeptidases / ADAM17 Protein / COVID-19 / Neoplasms Type of study: Observational study Topics: Long Covid Limits: Humans Language: English Journal: Br J Cancer Year: 2021 Document Type: Article Affiliation country: S41416-020-01246-0